Real-world Data of Clazosentan in Combination Therapy for Aneurysmal Subarachnoid Hemorrhage: a Multicenter Retrospective Cohort Study

Overview

Journal Neurosurg Rev

Specialty Neurosurgery

Date 2023 Aug 9

PMID 37555872

Authors

Shinsuke Muraoka

Takumi Asai

Takahiko Fukui

Shinji Ota

Shinji Shimato

Naoki Koketsu

Toshihisa Nishizawa

Yoshio Araki

Ryuta Saito

Affiliations

Soon will be listed here.

Abstract

Aneurysmal subarachnoid hemorrhage (aSAH) may lead to cerebral vasospasm, significantly associated with morbidity and mortality. In double-blind, placebo-controlled phase 3 studies, clazosentan reduces cerebral vasospasm-related morbidity and all-cause mortality in patients with aSAH. There are no reports about the clinical efficacy of clazosentan combination therapy with some other drugs. Initially, we explored the efficacy of clazosentan combination therapy with cilostazol, statin, and antiepileptic drugs. Subsequently, we assessed the add-on effect of fasudil to clazosentan combination therapy for aSAH patients. This multicenter, retrospective, observational cohort study included Japanese patients with aSAH between June 2022 and March 2023. The primary outcome was the ordinal score on the modified Rankin Scale (mRS; range, 0-6, with elevated scores indicating greater disability) at discharge. Among the 47 cases (women 74.5%; age 64.4 ± 15.0 years) undergoing clazosentan combination therapy, 29 (61.7%) resulted in favorable outcomes. Overall, vasospasm occurred in 16 cases (34.0%), with four cases (8.5%) developing vasospasm-related delayed cerebral ischemia (DCI). Both hypotension and vasospasm-related DCI were related to unfavorable outcome at discharge. Fasudil were added in 18 (38.3%) cases. Despite adding fasudil to clazosentan combination therapy, the incidence of aSAH-related vasospasm did not decrease. Added-on fasudil to combination therapy related to pulmonary edema, vasospasm, and vasospasm-related DCI, and unfavorable outcomes. Clazosentan combination therapy could potentially result in favorable outcomes for aSAH patients to prevent post-aSAH vasospasm-related DCI. The add-on effect of fasudil to combination therapy did not demonstrate a significant impact in reducing aSAH-related vasospasm or improving outcomes at discharge.

Citing Articles

Effects of the Japanese traditional medicine Goreisan on adverse events affecting mucosal edema in patients with subarachnoid hemorrhage treated with clazosentan.

Akamatsu Y, Chida K, Miyoshi K, Kojima D, Yoshida K, Misaki T Neurosurg Rev. 2025; 48(1):293.

PMID: 40069304 DOI: 10.1007/s10143-025-03394-4.

Clazosentan-induced reversible focal brain edema in basal ganglia following aneurysmal subarachnoid hemorrhage treatment: illustrative case.

Oishi H, Kato T, Hasegawa T, Naito T, Mizuno A, Kageyama A J Neurosurg Case Lessons. 2024; 8(20).

PMID: 39527806 PMC: 11558685. DOI: 10.3171/CASE24567.

Symptomatic Vasospasm Refractory to Clazosentan after Subarachnoid Hemorrhage of Ruptured Vertebral Artery Dissecting Aneurysm: Clinical Implications from Two Contrasting Cases.

Yoshida Y, Mutoh T, Moroi J, Ishikawa T Medicina (Kaunas). 2024; 60(9).

PMID: 39336584 PMC: 11434283. DOI: 10.3390/medicina60091543.

Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study.

Sakata H, Kanoke A, Uchida H, Haryu S, Omodaka S, Kimura N Front Neurol. 2024; 15:1413632.

PMID: 38903164 PMC: 11187092. DOI: 10.3389/fneur.2024.1413632.

Comparison of efficacy between clazosentan and fasudil hydrochloride-based management of vasospasm after subarachnoid hemorrhage focusing on older and WFNS grade V patients: a single-center experience in Japan.

Mochizuki T, Ryu B, Shima S, Kamijyo E, Ito K, Ando T Neurosurg Rev. 2024; 47(1):113.

PMID: 38472507 DOI: 10.1007/s10143-024-02345-9.

References

Anetsberger A, Gempt J, Blobner M, Ringel F, Bogdanski R, Heim M . Impact of Goal-Directed Therapy on Delayed Ischemia After Aneurysmal Subarachnoid Hemorrhage: Randomized Controlled Trial. Stroke. 2020; 51(8):2287-2296. DOI: 10.1161/STROKEAHA.120.029279. View

Barth M, Capelle H, Munch E, Thome C, Fiedler F, Schmiedek P . Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series. Acta Neurochir (Wien). 2007; 149(9):911-8. DOI: 10.1007/s00701-007-1249-3. View

Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K . Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg. 2003; 238(5):641-8. PMC: 1356139. DOI: 10.1097/01.sla.0000094387.50865.23. View

Bruder N, Rabinstein A . Cardiovascular and pulmonary complications of aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011; 15(2):257-69. DOI: 10.1007/s12028-011-9598-4. View

Connolly Jr E, Rabinstein A, Carhuapoma J, Derdeyn C, Dion J, Higashida R . Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke. 2012; 43(6):1711-37. DOI: 10.1161/STR.0b013e3182587839. View

Crowley R, Medel R, Kassell N, Dumont A . New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage. Drug Discov Today. 2008; 13(5-6):254-60. DOI: 10.1016/j.drudis.2007.11.010. View

de Oliveira J, Beck J, Ulrich C, Rathert J, Raabe A, Seifert V . Comparison between clipping and coiling on the incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurosurg Rev. 2006; 30(1):22-30. DOI: 10.1007/s10143-006-0045-5. View

Dorsch N . Therapeutic approaches to vasospasm in subarachnoid hemorrhage. Curr Opin Crit Care. 2002; 8(2):128-33. DOI: 10.1097/00075198-200204000-00007. View

Endo H, Hagihara Y, Kimura N, Takizawa K, Niizuma K, Togo O . Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg. 2022; 137(6):1707-1717. DOI: 10.3171/2022.2.JNS212914. View

10.

Fujimura M, Joo J, Kim J, Hatta M, Yokoyama Y, Tominaga T . Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients. Cerebrovasc Dis. 2017; 44(1-2):59-67. PMC: 5475234. DOI: 10.1159/000475824. View

11.

Geraghty J, Testai F . Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: Beyond Vasospasm and Towards a Multifactorial Pathophysiology. Curr Atheroscler Rep. 2017; 19(12):50. DOI: 10.1007/s11883-017-0690-x. View

12.

Hashimoto A, Tanaka M, Takeda S, Ito H, Nagano K . Cilostazol Induces PGI2 Production via Activation of the Downstream Epac-1/Rap1 Signaling Cascade to Increase Intracellular Calcium by PLCε and to Activate p44/42 MAPK in Human Aortic Endothelial Cells. PLoS One. 2015; 10(7):e0132835. PMC: 4504471. DOI: 10.1371/journal.pone.0132835. View

13.

Ito H, Fukunaga M, Suzuki H, Miyakoda G, Ishikawa M, Yabuuchi Y . Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. Neurobiol Dis. 2008; 32(1):157-61. DOI: 10.1016/j.nbd.2008.07.004. View

14.

Kassell N, Torner J, Jane J, Haley Jr E, Adams H . The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2: Surgical results. J Neurosurg. 1990; 73(1):37-47. DOI: 10.3171/jns.1990.73.1.0037. View

15.

Kramer A, Fletcher J . Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: a meta-analysis. Stroke. 2009; 40(10):3403-6. DOI: 10.1161/STROKEAHA.109.560243. View

16.

Lee V, Oh J, Mulvagh S, Wijdicks E . Mechanisms in neurogenic stress cardiomyopathy after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2007; 5(3):243-9. DOI: 10.1385/NCC:5:3:243. View

17.

Lee V, Connolly H, Fulgham J, Manno E, Brown Jr R, Wijdicks E . Tako-tsubo cardiomyopathy in aneurysmal subarachnoid hemorrhage: an underappreciated ventricular dysfunction. J Neurosurg. 2007; 105(2):264-70. DOI: 10.3171/jns.2006.105.2.264. View

18.

Lucke-Wold B, Logsdon A, Manoranjan B, Turner R, McConnell E, Vates G . Aneurysmal Subarachnoid Hemorrhage and Neuroinflammation: A Comprehensive Review. Int J Mol Sci. 2016; 17(4):497. PMC: 4848953. DOI: 10.3390/ijms17040497. View

19.

Loch Macdonald R, Kassell N, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S . Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008; 39(11):3015-21. DOI: 10.1161/STROKEAHA.108.519942. View

20.

Loch Macdonald R, Higashida R, Keller E, Mayer S, Molyneux A, Raabe A . Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011; 10(7):618-25. DOI: 10.1016/S1474-4422(11)70108-9. View